Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.
Mosquera-Orgueira A, Arellano-Rodrigo E, Garrote M, Martín I, Pérez-Encinas M, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, Heras NL, Magro E, Pérez-Míguez C, Crucitti D, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Nangalia J, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC; Spanish MPN Group (GEMFIN). Mosquera-Orgueira A, et al. Among authors: ayala r. Hemasphere. 2024 Mar 20;8(3):e60. doi: 10.1002/hem3.60. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38510992 Free PMC article. No abstract available.
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Among authors: ayala r. Ann Hematol. 2015 Jun;94(6):911-8. doi: 10.1007/s00277-015-2330-2. Epub 2015 Feb 14. Ann Hematol. 2015. PMID: 25680896
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Alvarez-Larrán A, et al. Among authors: ayala r. Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12. Haematologica. 2016. PMID: 27175028 Free PMC article.
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.
Alonso-Dominguez JM, Casado LF, Anguita E, Gomez-Casares MT, Buño I, Ferrer-Marín F, Arenas A, Del Orbe R, Ayala R, Llamas P, Salgado RN, Osorio S, Sanchez-Godoy P, Burgaleta C, Mahíllo-Fernández I, Garcia-Gutierrez V, Steegmann JL, Martinez-Lopez J. Alonso-Dominguez JM, et al. Among authors: ayala r. PLoS One. 2017 Jul 13;12(7):e0181366. doi: 10.1371/journal.pone.0181366. eCollection 2017. PLoS One. 2017. PMID: 28704552 Free PMC article.
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
Colom-Fernández B, Kreutzman A, Marcos-Jiménez A, García-Gutiérrez V, Cuesta-Mateos C, Portero-Sainz I, Pérez-García Y, Casado LF, Sánchez-Guijo F, Martínez-López J, Ayala RM, Boqué C, Xicoy B, Montero I, Soto C, Paz R, Silva G, Vega-Piris L, Steegmann JL, Muñoz-Calleja C. Colom-Fernández B, et al. Among authors: ayala rm. Front Pharmacol. 2019 Nov 25;10:1340. doi: 10.3389/fphar.2019.01340. eCollection 2019. Front Pharmacol. 2019. PMID: 31824308 Free PMC article.
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Pastor-Galán I, et al. Among authors: ayala r. Med Clin (Barc). 2020 Aug 28;155(4):152-158. doi: 10.1016/j.medcli.2019.11.007. Epub 2020 Jan 21. Med Clin (Barc). 2020. PMID: 31980217 English, Spanish.
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hernández-Rivas JM, Hernández-Boluda JC, Fernandez-Rodriguez C, Luño E, García Hernandez C, Kerguelen A, Fiallo-Suárez DV, Gómez-Casares MT, Ayala R, Vélez P, Boqué C, García-Gutierrez V, Arrizabalaga B, Estrada N, Cifuentes R, Arcas I, de Los Reyes-García AM, Besses C, Vicente V, Alvarez-Larrán A, Teruel-Montoya R, González-Conejero R, Martínez C; GEMFIN Group. Ferrer-Marín F, et al. Among authors: ayala r. Leukemia. 2020 Oct;34(10):2648-2659. doi: 10.1038/s41375-020-0767-3. Epub 2020 Feb 27. Leukemia. 2020. PMID: 32107471
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas). Alvarez-Larrán A, et al. Among authors: ayala r. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13. Cancer. 2022. PMID: 35417564 Free PMC article.
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J. Sánchez R, et al. Among authors: ayala r. Sci Rep. 2022 Jul 29;12(1):13057. doi: 10.1038/s41598-022-17271-3. Sci Rep. 2022. PMID: 35906470 Free PMC article.
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, Raya JM, Pérez-Encinas M, Ayala R, Ferrer-Marín F, Velez P, Mora E, Fox ML, Hernández-Rivas JM, Xicoy B, Mata-Vázquez MI, García-Fortes M, Pérez-López R, Angona A, Cuevas B, Senín A, Ramírez MJ, Ramírez-Payer A, Gómez-Casares MT, Martínez-Valverde C, Magro E, Steegmann JL, Durán MA, García-Hernández C, Gasior M, de Villambrosia SG, Alvarez-Larrán A, Pereira A; Spanish MPN Group (GEMFIN). Hernández-Boluda JC, et al. Among authors: ayala r. Br J Haematol. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. Epub 2022 Sep 12. Br J Haematol. 2022. PMID: 36089912
355 results